Docon Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a major promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostics chain, raising Rs 986 crore. The transaction, executed through multiple bulk and block deals, was completed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on Thursday.

Details of the Transaction

Docon offloaded a total of 1,57,69,696 equity shares, with more than 1.31 crore shares sold via block deals and an additional 10 lakh shares through bulk deals on the NSE. Another 16.01 lakh shares were sold through a bulk deal on the BSE. The shares were traded within a price range of Rs 624 to Rs 631.71 apiece, resulting in a total transaction value of Rs 985.86 crore.

Impact on Docon's Stake

Following this sale, Docon's ownership in Thyrocare Technologies has decreased from 60.92% to 51.02%. This stake reduction comes after Docon previously sold a 10% stake in Thyrocare for Rs 667 crore in October of the previous year.

Investor Participation

The stake sale attracted numerous institutional investors, including HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance companies such as Kotak Mahindra Life Insurance and Tata AIA Life Insurance also participated, alongside global investors including Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.

The transaction appears to have positively influenced Thyrocare Technologies' stock performance, with shares rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE following the announcement.

Market Reaction and Future Prospects

The recent stake sale by Docon Technologies underscores the continued interest of institutional and global investors in India's healthcare sector, particularly in diagnostics. While the exact details of other buyers involved in the bulk deals remain undisclosed, the transaction reflects a robust demand for shares in Thyrocare Technologies.

As the market digests this significant divestment, stakeholders will be watching closely to see how Thyrocare Technologies leverages this influx of capital and how Docon's strategic decisions impact its future holdings in the company.